Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.50 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA7 | P43166 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.48 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8151711 | 0.96 | HSP90AB1 (0.92) | HSP90AB1ALDH1A1GAAGFERCYP4F2 | |
| SCHEMBL2973152 | 0.88 | HSP90AB1 (0.79) | HSP90AB1ALDH1A1GAAGFERCYP4F2 | |
| SCHEMBL14626268 | 0.88 | HSP90AB1 (0.79) | HSP90AB1ALDH1A1GAAGFERCYP4F2 | |
| SCHEMBL2984242 | 0.87 | HSP90AB1 (0.76) | HSP90AB1ALDH1A1GAAGFERCYP4F2 | |
| SCHEMBL27725733 | 0.87 | HSP90AB1 (0.76) | HSP90AB1ALDH1A1GAAGFERCYP4F2 | |
| SCHEMBL2977953 | 0.87 | HSP90AB1 (0.76) | HSP90AB1ALDH1A1GAAGFERCYP4F2 | |
| SCHEMBL350066 | 0.87 | HSP90AB1 (0.76) | HSP90AB1ALDH1A1GAAGFERCYP4F2 | |
| SCHEMBL21891794 | 0.86 | HSP90AB1 (0.75) | HSP90AB1ALDH1A1GAAGFERCYP4F2 | |
| SCHEMBL9202392 | 0.82 | HSP90AB1 (0.69) | HSP90AB1ALDH1A1GAAGFERCYP4F2 | |
| SCHEMBL5051707 | 0.82 | HSP90AB1 (0.69) | HSP90AB1ALDH1A1GAAGFERCYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 313 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116425192-B | Powder material special for PS-PVD, preparation method and application | 北京伽瓦新材料科技有限公司 | 2023-11-14 | — | — | CN | claimed |
| CN-116425192-A | Powder material special for PS-PVD, preparation method and application | 北京伽瓦新材料科技有限公司 | 2023-07-14 | — | — | CN | claimed |
| EP-4320138-B1 | PSEUDO SOLID PHASE PROTECTING GROUP AND METHODS FOR THE SYNTHESIS OF OLIGONUCLEOTIDES AND OLIGONUCLEOTIDE CONJUGATES | BACHEM AG (CH) | 2026-04-01 | — | — | EP | disclosed |
| US-20250282813-A1 | PSEUDO SOLID PHASE PROTECTING GROUP AND METHODS FOR THE SYNTHESIS OF OLIGONUCLEOTIDES AND OLIGONUCLEOTIDE CONJUGATES | BACHEM HOLDING AG (CH) | 2025-09-11 | — | — | US | disclosed |
| US-11964956-B2 | Cannabinergic compounds and uses thereof | NORTHEASTERN UNIVERSITY (US) | 2024-04-23 | — | — | US | disclosed |
| EP-4320138-A1 | PSEUDO SOLID PHASE PROTECTING GROUP AND METHODS FOR THE SYNTHESIS OF OLIGONUCLEOTIDES AND OLIGONUCLEOTIDE CONJUGATES | Bachem Holding AG (CH) | 2024-02-14 | — | — | EP | disclosed |
| US-20240025858-A1 | CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHOD OF PREPARATION THEREOF | JAZZ PHARMACEUTICALS RESEARCH UK LIMITED (GB) | 2024-01-25 | — | — | US | disclosed |
| US-20240025858-A1 | CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHOD OF PREPARATION THEREOF | JAZZ PHARMACEUTICALS RESEARCH UK LIMITED (GB) | 2024-01-25 | — | — | US | disclosed |
| CN-116425192-B | Powder material special for PS-PVD, preparation method and application | 北京伽瓦新材料科技有限公司 | 2023-11-14 | — | — | CN | disclosed |
| EP-4262980-A1 | CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHOD OF PREPARATION THEREOF | GW Research Limited (GB) | 2023-10-25 | — | — | EP | disclosed |
| CN-116685569-A | Cannabinoid derivatives as pharmaceutically active compounds and process for their preparation | 吉伟研究有限公司 | 2023-09-01 | — | — | CN | disclosed |
| EP-1337527-A1 | INDOLYLMALEIMIDE DERIVATIVES AS PROTEIN KINASE C INHIBITORS | Novartis AG (CH) | 2003-08-27 | — | — | EP | disclosed |
| US-6596772-B1 | Relates to trifluoromethyl sulfonyl and trifluoromethyl sulfonamido compounds and the physiologically acceptable salts and the prodrugs thereof. These compounds are expected to modulate the activity of protein tyrosine enzymes which are | SUGEN, INC. | 2003-07-22 | — | — | US | disclosed |
| US-20030069424-A1 | Indolylmaleimide derivatives | NOVARTIS AG (CH) | 2003-04-10 | — | — | US | disclosed |
| EP-1268525-A2 | MACROCYCLIC NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS COMPRISING N-CYCLIC P2 MOIETIES | SCHERING CORPORATION (US) | 2003-01-02 | — | — | EP | disclosed |
| US-20020107181-A1 | Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising N-cyclic P2 moieties | SCHERING CORPORATION | 2002-08-08 | — | — | US | disclosed |
| EP-1212296-A1 | PHOSPHATE MIMICS AND METHODS OF TREATMENT USING PHOSPHATASE INHIBITORS | Sugen, Inc. (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2002038561-A1 | INDOLYLMALEIMIDE DERIVATIVES AS PROTEIN KINASE C INHIBITORS | NOVARTIS AG (CH) | 2002-05-16 | — | — | WO | disclosed |
| WO-2001077113-A2 | MACROCYCLIC NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS COMPRISING N-CYCLIC P2 MOIETIES | SCHERING CORPORATION (US) | 2001-10-18 | — | — | WO | disclosed |
| WO-2001016097-A1 | PHOSPHATE MIMICS AND METHODS OF TREATMENT USING PHOSPHATASE INHIBITORS | SUGEN, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11964956-B2 | Cannabinergic compounds and uses thereof | CNR2, CNR1, GPR18 | HSP90AB1 701/4885ALDH1A1 2734/4885GAA 796/4885 |
| US-20030069424-A1 | Indolylmaleimide derivatives | NFATC1, INMT, IDO1 | HSP90AB1 3709/4885ALDH1A1 1752/4885GAA 3119/4885 |
| US-20240025858-A1 | CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHOD OF PREPARATION THEREOF | CNR1, CNR2, FAAH | HSP90AB1 3897/4885ALDH1A1 3920/4885GAA 1878/4885 |
| US-20020107181-A1 | Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising N-cyclic P2 moieties | HPN, TMPRSS15, HAVCR2 | HSP90AB1 2862/4885ALDH1A1 2837/4885GAA 1668/4885 |
| US-20250282813-A1 | PSEUDO SOLID PHASE PROTECTING GROUP AND METHODS FOR THE SYNTHESIS OF OLIGONUCLEOTIDES AND OLIGONUCLEOTIDE CONJUGATES | POLR2H, POLR2E, SUB1 | HSP90AB1 3834/4885ALDH1A1 2910/4885GAA 3974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.